First Eagle Investment Management’s Cascadian Therapeutics CASC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
– Sell
-24,999
Closed -$108K – 343
2016
Q4
$108K Sell
24,999
-41,668
-63% -$269K ﹤0.01% 264
2016
Q3
$656K Hold
66,667
– – ﹤0.01% 253
2016
Q2
$377K Buy
66,667
+16,667
+33% +$113K ﹤0.01% 276
2016
Q1
$381K Hold
50,000
– – ﹤0.01% 265
2015
Q4
$666K Buy
+50,000
New +$861K ﹤0.01% 238
2015
Q2
– Sell
-216,667
Closed -$2.12M – 335
2015
Q1
$2.12M Buy
+216,667
New +$2.12M 0.01% 206
2014
Q3
– Sell
-397,340
Closed -$7.72M – 356
2014
Q2
$7.72M Sell
397,340
-56,825
-13% -$1M 0.02% 179
2014
Q1
$8.15M Buy
454,165
+16,667
+4% +$274K 0.02% 147
2013
Q4
$4.62M Buy
437,498
+58,283
+15% +$652K 0.01% 171
2013
Q3
$4.69M Buy
379,215
+163,298
+76% +$1.72M 0.01% 182
2013
Q2
$2.02M Buy
+215,917
New +$2.77M 0.01% 225

Other funds holding CASC

First Eagle Investment Management's CASC Position: Q1 2017 in Review

First Eagle Investment Management sold out of Cascadian Therapeutics (CASC) in Q1 2017, closing a stake of 24,999 shares — an estimated $108K sold.

First Eagle Investment Management first reported a position in CASC in Q2 2013 and held it in 11 quarters. The position peaked at $8.15M in Q1 2014. 78 funds tracked by Wall St. Rank hold CASC as of Q1 2017.

  • First Eagle Investment Management reported no remaining Cascadian Therapeutics position as of Q1 2017 after selling out during the quarter.
  • First Eagle Investment Management sold 24,999 Cascadian Therapeutics shares in Q1 2017, an estimated $108K.
  • First Eagle Investment Management first reported a position in Cascadian Therapeutics in Q2 2013 and held it in 11 quarters.
  • First Eagle Investment Management's Cascadian Therapeutics position peaked at $8.15M in Q1 2014.
  • 78 funds tracked by Wall St. Rank held Cascadian Therapeutics as of Q1 2017.

Based on First Eagle Investment Management's 13F filing for Q1 2017, filed 5 May 2017.